Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Nicholas Cothros, Alex Medina & Tamara Pringsheim. (2020) Current pharmacotherapy for tic disorders. Expert Opinion on Pharmacotherapy 21:5, pages 567-580.
Read now
Read now
Marco Solmi, Giorgio Pigato, John M Kane & Christoph U Correll. (2018) Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Design, Development and Therapy 12, pages 1215-1238.
Read now
Read now
Harini Sarva & Claire Henchcliffe. (2018) Valbenazine as the first and only approved treatment for adults with tardive dyskinesia. Expert Review of Clinical Pharmacology 11:3, pages 209-217.
Read now
Read now
Lauren C. Seeberger & Robert A. Hauser. (2017) Valbenazine for the treatment of tardive dyskinesia. Expert Opinion on Pharmacotherapy 18:12, pages 1279-1287.
Read now
Read now
Joseph Jankovic. (2016) Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opinion on Pharmacotherapy 17:18, pages 2461-2470.
Read now
Read now
Ricardo P. Garay, Leslie Citrome, Ludovic Samalin, Chen-Chung Liu, Morten S. Thomsen, Christoph U. Correll, Ahcène Hameg & Pierre-Michel Llorca. (2016) Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opinion on Pharmacotherapy 17:7, pages 921-936.
Read now
Read now
Articles from other publishers (30)
Alexander J. Poznanski & Esther Akinyemi. (2022) Recent Advances in Psychopharmacology. Advances in Psychiatry and Behavioral Health 2:1, pages 253-266.
Crossref
Crossref
Wenyan Wang, Shilan Lin, Guangying Du, Xinfa Bai, Jing Lu, Liang Ye, Hongbo Wang, Rui Zhang & Jingwei Tian. (2022) 9-Cyclopropylmethoxy-dihydrotetrabenazine and its stereoisomers as vesicular monoamine transporter-2 inhibitors. Future Medicinal Chemistry 14:13, pages 991-1003.
Crossref
Crossref
Meenakshi Dhanawat, Sumeet Gupta, Rina Das & Dinesh K. Mehta. (2022) LAT1: A POTENTIAL CEREBROVASCULAR TARGET TO BREACH BBB. Indian Drugs 59:03, pages 7-17.
Crossref
Crossref
Wenyan Wang, Guangying Du, Shilan Lin, Jing Liu, Huijie Yang, Dawei Yu, Liang Ye, Fangxia Zou, Hongbo Wang, Rui Zhang & Jingwei Tian. (2021) (+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia. Frontiers in Pharmacology 12.
Crossref
Crossref
Debdatta Saha & T. M. Vasuprada. (2021) Understanding the Trade-offs in Drug Development: Retrospective on Lessons from the Early Phase of the COVID-19 Pandemic. Journal of Developing Societies 37:3, pages 329-362.
Crossref
Crossref
Harshit Gupta, Alycee R. Moity, Allison Jumonville, Sarah Kaufman, Amber N. Edinoff & Alan D. Kaye. (2021) Valbenazine for the Treatment of Adults with Tardive Dyskinesia. Health Psychology Research 9:1.
Crossref
Crossref
Stewart A. Factor. (2020) Management of Tardive Syndrome: Medications and Surgical Treatments. Neurotherapeutics 17:4, pages 1694-1712.
Crossref
Crossref
Hassaan H. Bashir & Joseph Jankovic. (2020) Treatment of Tardive Dyskinesia. Neurologic Clinics 38:2, pages 379-396.
Crossref
Crossref
Mei Huang, Wenqi He, Lakshmi Rajagopal, Andrea Kudwa, Dimitri E. Grigoriadis & Herbert Y. Meltzer. (2020) Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action. Pharmacology Biochemistry and Behavior 190, pages 172872.
Crossref
Crossref
Kristen A. Stout, Amy R. Dunn, Carlie Hoffman & Gary W. Miller. (2019) The Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance. ACS Chemical Neuroscience 10:9, pages 3927-3938.
Crossref
Crossref
Alyssa M. Peckham & Jessica A. Nicewonder. (2018) VMAT2 Inhibitors for Tardive Dyskinesia—Practice Implications. Journal of Pharmacy Practice 32:4, pages 450-457.
Crossref
Crossref
Ibraheem Husain, Saima Zameer, Tushar Madaan, Akram Minhaj, Wasim Ahmad, Asif Iqubaal, Abuzer Ali & Abul Kalam Najmi. (2019) Exploring the multifaceted neuroprotective actions of Emblica officinalis (Amla): a review. Metabolic Brain Disease 34:4, pages 957-965.
Crossref
Crossref
Natalie Witek & Cynthia Comella. (2019) Valbenazine in the treatment of tardive dyskinesia. Neurodegenerative Disease Management 9:2, pages 73-81.
Crossref
Crossref
Adam Margolius & Hubert H. Fernandez. (2019) Current treatment of tardive dyskinesia. Parkinsonism & Related Disorders 59, pages 155-160.
Crossref
Crossref
Mehmet Emin Demirkol, Şilan Şenbayram, Gökçen Doğangüneş & Lut Tamam. (2018) Tardif Diskinezi ve Tedavi Yaklaşımları. Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry 10:2, pages 239-254.
Crossref
Crossref
Clement C. Zai, Miriam S. Maes, Arun K. Tiwari, Gwyneth C. Zai, Gary Remington & James L. Kennedy. (2018) Genetics of tardive dyskinesia: Promising leads and ways forward. Journal of the Neurological Sciences 389, pages 28-34.
Crossref
Crossref
Laura M. Scorr & Stewart A. Factor. (2018) VMAT2 inhibitors for the treatment of tardive dyskinesia. Journal of the Neurological Sciences 389, pages 43-47.
Crossref
Crossref
Clement C. Zai, Arun K. Tiwari, Gwyneth C. Zai, Miriam S. Maes & James L. Kennedy. (2018) New findings in pharmacogenetics of schizophrenia. Current Opinion in Psychiatry 31:3, pages 200-212.
Crossref
Crossref
Stanley N Caroff, Saurabh Aggarwal & Charles Yonan. (2018) Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review. Journal of Comparative Effectiveness Research 7:2, pages 135-148.
Crossref
Crossref
Thomas Müller. (2017) Deuteriertes Tetrabenazin verringert unkontrollierte Bewegungen. InFo Neurologie & Psychiatrie 19:9, pages 18-18.
Crossref
Crossref
Dimitri E. Grigoriadis, Evan Smith, Sam R. J. Hoare, Ajay Madan & Haig Bozigian. (2017) Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites. Journal of Pharmacology and Experimental Therapeutics 361:3, pages 454-461.
Crossref
Crossref
Davide MartinoFrancesca Morgante. (2017) Movement disorders and chronic psychosis. Neurology Clinical Practice 7:2, pages 163-169.
Crossref
Crossref
Jonathan M. Meyer. (2017) Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectrums 21:S1, pages 13-24.
Crossref
Crossref
Leslie Citrome. (2017) Emerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next?. CNS Spectrums 21:S1, pages 1-12.
Crossref
Crossref
Dhanya Vijayakumar & Joseph Jankovic. (2016) Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. Drugs 76:7, pages 779-787.
Crossref
Crossref
L. Citrome. (2016) Breakthrough drugs for the interface between psychiatry and neurology. International Journal of Clinical Practice 70:4, pages 298-299.
Crossref
Crossref
Kurt Samson. (2016) News from the AAN Annual Meeting. Neurology Today 16:8, pages 1.
Crossref
Crossref
Subhashie Wijemanne, Joseph Jankovic & Randolph W. Evans. (2016) Movement Disorders From the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine. Headache: The Journal of Head and Face Pain 56:1, pages 153-161.
Crossref
Crossref
Lindsey R. Orgren, Emily E. Maverick & Christopher C. Marvin. (2015) Synthesis of (±)-Tetrabenazine by Visible Light Photoredox Catalysis. The Journal of Organic Chemistry 80:24, pages 12635-12640.
Crossref
Crossref
Joseph Jankovic, Susan Bressman, William Dauer & Un Jung Kang. (2015) Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions. Movement Disorders 30:14, pages 1862-1869.
Crossref
Crossref